Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task.

Vardigan JD, Converso A, Hutson PH, Uslaner JM.

J Neurogenet. 2011 Dec;25(4):120-6. doi: 10.3109/01677063.2011.630494. Epub 2011 Nov 9.

PMID:
22070409
2.

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.

Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE, Mullins D, Hyde LA, Eschle BK, Turnbull Z, Sloan H, Guzzi M, Zhang X, Wang A, Rindgen D, Mazzola R, Vivian JA, Eddins D, Uslaner JM, Bednar R, Gambone C, Le-Mair W, Marino MJ, Sachs N, Xu G, Parmentier-Batteur S.

Neuropharmacology. 2011 Sep;61(4):665-76. doi: 10.1016/j.neuropharm.2011.05.009. Epub 2011 May 19.

PMID:
21619887
3.

Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.

Su T, Zhang T, Xie S, Yan J, Wu Y, Li X, Huang L, Luo HB.

Sci Rep. 2016 Feb 25;6:21826. doi: 10.1038/srep21826.

4.

Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP.

Kroker KS, Rast G, Giovannini R, Marti A, Dorner-Ciossek C, Rosenbrock H.

Neuropharmacology. 2012 Apr;62(5-6):1964-74. doi: 10.1016/j.neuropharm.2011.12.021. Epub 2012 Jan 4.

PMID:
22245562
5.

PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.

Kroker KS, Mathis C, Marti A, Cassel JC, Rosenbrock H, Dorner-Ciossek C.

Neurobiol Aging. 2014 Sep;35(9):2072-8. doi: 10.1016/j.neurobiolaging.2014.03.023. Epub 2014 Mar 26.

PMID:
24746365
6.

Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit?

Ghavami A, Hirst WD, Novak TJ.

Drugs R D. 2006;7(2):63-71. Review.

PMID:
16542053
7.

The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.

van der Staay FJ, Rutten K, Bärfacker L, Devry J, Erb C, Heckroth H, Karthaus D, Tersteegen A, van Kampen M, Blokland A, Prickaerts J, Reymann KG, Schröder UH, Hendrix M.

Neuropharmacology. 2008 Oct;55(5):908-18. doi: 10.1016/j.neuropharm.2008.07.005. Epub 2008 Jul 12.

PMID:
18674549
8.

Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.

de Bruin NM, Prickaerts J, van Loevezijn A, Venhorst J, de Groote L, Houba P, Reneerkens O, Akkerman S, Kruse CG.

Neurobiol Learn Mem. 2011 Sep;96(2):392-402. doi: 10.1016/j.nlm.2011.06.015. Epub 2011 Jul 3.

PMID:
21757018
9.

Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline.

Ramos BP, Birnbaum SG, Lindenmayer I, Newton SS, Duman RS, Arnsten AF.

Neuron. 2003 Nov 13;40(4):835-45.

10.

Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.

Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M, Helal CJ, Claffey MM, Tuttle JB, Coffman KJ, Liu S, Nelson F, Kleiman RJ, Menniti FS, Schmidt CJ, Vanase-Frawley M, Liras S.

J Med Chem. 2012 Nov 8;55(21):9045-54. doi: 10.1021/jm3007799. Epub 2012 Jul 25.

PMID:
22780914
11.

Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line.

Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M.

Mol Pharmacol. 2005 Dec;68(6):1775-81. Epub 2005 Sep 8.

12.

Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.

Shao YX, Huang M, Cui W, Feng LJ, Wu Y, Cai Y, Li Z, Zhu X, Liu P, Wan Y, Ke H, Luo HB.

J Med Chem. 2014 Dec 26;57(24):10304-13. doi: 10.1021/jm500836h. Epub 2014 Dec 8.

13.

Phosphodiesterase inhibitors for cognitive enhancement.

Rose GM, Hopper A, De Vivo M, Tehim A.

Curr Pharm Des. 2005;11(26):3329-34. Review.

PMID:
16250839
14.

Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms.

Reneerkens OA, Rutten K, Akkerman S, Blokland A, Shaffer CL, Menniti FS, Steinbusch HW, Prickaerts J.

Neurobiol Learn Mem. 2012 May;97(4):370-9. doi: 10.1016/j.nlm.2012.02.008. Epub 2012 Mar 8.

PMID:
22426465
15.

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.

Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ.

J Pharmacol Exp Ther. 2012 May;341(2):396-409. doi: 10.1124/jpet.111.191353. Epub 2012 Feb 10.

16.
17.

Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468.

Saravani R, Karami-Tehrani F, Hashemi M, Aghaei M, Edalat R.

Cell Prolif. 2012 Jun;45(3):199-206. doi: 10.1111/j.1365-2184.2012.00819.x. Epub 2012 Apr 2.

PMID:
22469131
18.

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.

Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD, Eddins D, Toolan DM, Kandebo M, Yao L, Raheem IT, Schreier JD, Breslin MJ, Coleman PJ, Renger JJ.

Neuropharmacology. 2013 Jan;64:215-23. doi: 10.1016/j.neuropharm.2012.06.013. Epub 2012 Jun 27.

PMID:
22750078
19.

The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.

Shiraishi E, Suzuki K, Harada A, Suzuki N, Kimura H.

J Pharmacol Exp Ther. 2016 Mar;356(3):587-95. doi: 10.1124/jpet.115.230482. Epub 2015 Dec 16.

20.

SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents.

de Bruin NM, Prickaerts J, Lange JH, Akkerman S, Andriambeloson E, de Haan M, Wijnen J, van Drimmelen M, Hissink E, Heijink L, Kruse CG.

Neurobiol Learn Mem. 2010 May;93(4):522-31. doi: 10.1016/j.nlm.2010.01.010. Epub 2010 Feb 2.

PMID:
20132903

Supplemental Content

Support Center